(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 March 2011 (03.03.2011)

PCT

(10) International Publication Number
WO 2011/025859 A1

(51) International Patent Classification:
C07D 495/04 (2006.01) *A61K 31/429* (2006.01)
C07D 513/04 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2010/046760

(22) International Filing Date:
26 August 2010 (26.08.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/237,227 26 August 2009 (26.08.2009) US
61/289,317 22 December 2009 (22.12.2009) US

(71) Applicant *(for all designated States except US)*: **CYLENE PHARMACEUTICALS, INC.** [US/US]; 5820 Nancy Ridge Drive, Suite 200, San Diego, California 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **PIERRE, Fabrice** [FR/US]; 3244 Caminito Eastbluff, #40, La Jolla, California 92037 (US). **HADDACH, Mustapha** [US/US]; 14744 Via Mantova, San Diego, California 92127 (US). **REGAN, Collin, F.** [US/US]; 981 North Vulcan, Encinitas, California 92024 (US). **RYCKMAN, David, M.** [US/US]; 5675 Willowmere Lane, San Diego, California 92130 (US).

(74) Agents: **WU, Nan** et al.; Cooley LLP, 777 6th Street, NW, Suite 1100, Washington, DC 20001 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

[Continued on next page]

(54) Title: CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS



(I)

(57) Abstract: The invention relates in part to molecules of formula (I) having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate protein kinase CK2 activity, Pim kinase activity and/or FMS-like tyrosine kinase (Fit) activity. The invention also relates in part to methods for using such molecules (I) wherein the substituents are defined as in the claims.

WO 2011/025859 A1

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*